Search results
Showing 8461 to 8475 of 8900 results
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guideline on renal replacement therapy and conservative management and for people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)
This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.